Scarica l'app Stockscreener
21.47
4.73%
0.97
Dopo l'orario di chiusura:
21.47
Precedente Chiudi:
$20.50
Aprire:
$20.2
Volume 24 ore:
919.28K
Relative Volume:
1.76
Capitalizzazione di mercato:
$1.41B
Reddito:
-
Utile/perdita netta:
$-137.95M
Rapporto P/E:
-8.5111
EPS:
-2.5226
Flusso di cassa netto:
$-107.11M
1 W Prestazione:
+13.48%
1M Prestazione:
+22.06%
6M Prestazione:
+28.49%
1 anno Prestazione:
+61.92%
Intervallo 1D:
$19.92
$21.50
Intervallo di 1 settimana:
$17.63
$21.50
Portata 52W:
$7.80
$21.50
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Nome
Bicara Therapeutics Inc
Settore
Industria
Telefono
617-468-4219
Indirizzo
116 HUNTINGTON AVENUE SUITE 703, BOSTON
Compare BCAX vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
21.47 | 1.41B | 0 | -137.95M | -107.11M | -2.5226 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-25 | Iniziato | BofA Securities | Buy |
| 2026-01-29 | Iniziato | Citizens JMP | Mkt Perform |
| 2026-01-08 | Iniziato | BTIG Research | Buy |
| 2025-12-18 | Iniziato | Mizuho | Neutral |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2025-05-23 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2025-04-17 | Iniziato | Wells Fargo | Underweight |
| 2025-02-06 | Iniziato | Wedbush | Outperform |
| 2024-12-06 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-05 | Iniziato | Rodman & Renshaw | Buy |
| 2024-10-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-08 | Iniziato | Morgan Stanley | Overweight |
| 2024-10-08 | Iniziato | Stifel | Buy |
| 2024-10-08 | Iniziato | TD Cowen | Buy |
Mostra tutto
Bicara Therapeutics Inc Borsa (BCAX) Ultime notizie
Bicara Therapeutics CEO Sold Over 8,000 Company Shares. Is the Stock a Sell or Buy? - AOL.com
Wall Street Analysts Believe Bicara Therapeutics Inc. (BCAX) Could Rally 54.85%: Here's is How to Trade - MSN
BCAX Technical Analysis & Stock Price Forecast - Intellectia AI
Bicara Therapeutics (BCAX) Is Up 13.5% After Breakthrough Status And Equity Raise Strengthen Cash Runway – Has The Bull Case Changed? - simplywall.st
Bicara Therapeutics Announces Inducement Grant - National Today
New Bicara hire gets stock option for 44,175 shares at $20.50 - Stock Titan
Bicara Therapeutics Inc. common stock (NASDAQ:BCAX) Q4 2025 earnings call transcript - MSN
HC Wainwright Has Bullish Estimate for BCAX Q1 Earnings - MarketBeat
Bicara Therapeutics stock hits 52-week high, reaching $20.42 By Investing.com - Investing.com South Africa
Is CareCloud (CCLD) Stock Outpacing Its Medical Peers This Year? - qz.com
Wall Street experts predict that Bicara Therapeutics Inc. (BCAX) has the potential to surge by 54.85%: Strategies for Trading - Bitget
Is CareCloud (CCLD) Performing Better Than Other Medical Stocks This Year? - Bitget
Bicara Therapeutics (NASDAQ:BCAX) Hits New 1-Year High Following Analyst Upgrade - MarketBeat
Bicara Therapeutics stock hits 52-week high, reaching $20.42 - Investing.com
Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), Bicara Therapeutics Inc. (BCAX) and Compass Therapeutics (CMPX) - The Globe and Mail
Bicara Therapeutics to rally around 121%? Here are 10 top analyst forecasts for Tuesday - MSN
Bicara: Maintaining 'Buy' Rating On Ficerafusp Alfa Phase 3 Advancement (NASDAQ:BCAX) - seekingalpha.com
Bicara Therapeutics (NASDAQ:BCAX) Price Target Raised to $16.00 at The Goldman Sachs Group - MarketBeat
Wells Fargo Maintains Rating on BCAX, Increases Price Target to - GuruFocus
Bicara Therapeutics (NASDAQ:BCAX) Given "Outperform" Rating at Wedbush - marketbeat.com
Bicara Therapeutics (NASDAQ:BCAX) Price Target Raised to $16.00 at Wells Fargo & Company - MarketBeat
Citizens Jmp Reiterates "Market Outperform" Rating for Bicara Therapeutics (NASDAQ:BCAX) - MarketBeat
BCAX Receives Updated Price Target from HC Wainwright & Co. | BC - GuruFocus
Bicara Therapeutics To Rally Around 121%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
HC Wainwright Increases Bicara Therapeutics (NASDAQ:BCAX) Price Target to $42.00 - MarketBeat
Bicara Therapeutics Inc. Common Stock Q4 2025 Earnings Call Summary - finance.yahoo.com
H.C. Wainwright raises Bicara Therapeutics stock price target on trial progress - Investing.com UK
H.C. Wainwright raises Bicara Therapeutics stock price target on trial progress By Investing.com - Investing.com South Africa
Citizens reiterates Bicara Therapeutics stock rating on trial progress By Investing.com - Investing.com Canada
Citizens reiterates Bicara Therapeutics stock rating on trial progress - Investing.com UK
Bicara Q4 2025 slides: breakthrough designation, pivotal study data By Investing.com - Investing.com South Africa
Value Recap: How is Bicara Therapeutics Inc managing supply chain issues2026 Key Lessons & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Bicara Therapeutics (Nasdaq: BCAX) outlines pivotal ficerafusp alfa cancer program - Stock Titan
Bicara Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Bicara Therapeutics Inc. Files 8-K with SEC Detailing Q4 2025 Financials and Corporate Updates - Minichart
Bicara Q4 2025 slides: breakthrough designation, pivotal study data - Investing.com
Bicara Therapeutics Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Bicara Therapeutics’ Q4 2025 sees stock surge on promising clinical data By Investing.com - Investing.com Australia
Earnings call transcript: Bicara Therapeutics’ Q4 2025 sees stock surge on promising clinical data - Investing.com Australia
Bicara Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - MarketScreener
Bicara Therapeutics 2025 Financial Update - AlphaStreet
Bicara Therapeutics reports fourth quarter and full year 2025 financial results and provides business update - marketscreener.com
Bicara Therapeutics (NASDAQ:BCAX) Announces Earnings Results - marketbeat.com
Cash runway to 2029 as Bicara (NASDAQ: BCAX) advances Phase 3 - Stock Titan
Bicara Therapeutics Inc. initiates Phase 3 trial with 1500 mg QW dose for FORTIFI-HN01 - Traders Union
Earnings Flash (BCAX) Bicara Therapeutics Posts Q4 Net Loss $0.68 a Share, vs. FactSet Est of $0.67 Loss - MarketScreener
Bicara moves head and neck cancer drug into Phase 3 after dose pick - Stock Titan
Bicara Therapeutics Inc (BCAX) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... By GuruFocus - Investing.com Canada
Aug Gainers: What are analysts price targets for Bicara Therapeutics IncQuarterly Portfolio Summary & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Aug Wrap: Will Bicara Therapeutics Inc benefit from rate cuts2026 Risk Factors & Weekly High Momentum Picks - baoquankhu1.vn
Bicara Therapeutics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Benzinga
Bicara Therapeutics Inc Azioni (BCAX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):